SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine
Shots:
- SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product
- SK bioscience will utilize its cell culture and recombinant protein capability- will initiate the production of the NVX-CoV2373 antigen at its facility in Andong L-house- South Korea- expected to begin in Aug’2020
- Additionally- the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare for equitable access to NVX-CoV2373 in global market and to make it available in South Korea
Ref: PRNewswire | Image: Novavax
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com